Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis

Hepatology

Volumn 45, Issue 1, 2007, Pages 62-71

  Mookerjee, Rajeshwar P ^a   Malaki, Mohammed ^a   Davies, Nathan A ^a   Hodges, Stephen J ^a   Dalton, R Neil ^b   Turner, Charles ^b   Sen, Sambit ^a   Williams, Roger ^a   Leiper, James ^a   Vallance, Patrick ^a   Jalan, Rajiv ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMINO ACID; BIOLOGICAL MARKER; DIMETHYLARGININASE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; PROTEIN ARGININE METHYLTRANSFERASE; SYMMETRIC DIMETHYLARGININE; UNCLASSIFIED DRUG;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEPATIC VEIN; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; SURVIVAL RATE; VENOUS PRESSURE;

ADULT; AGED; AMIDOHYDROLASES; ARGININE; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION REGULATION; HEPATITIS, ALCOHOLIC; HUMANS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, ALCOHOLIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN-ARGININE N-METHYLTRANSFERASE; REPRESSOR PROTEINS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 33846443945     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21491     Document Type: Article

References (38)

1. Tome S, Lucey MR. Review article: current management of alcoholic liver disease. Aliment Pharmacol Ther 2004;19:707-714.
2. Duvoux C, Radier C, Roudot-Thoraval F, Maille F, Anglade MC, Van Nhieu JT, et al. Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis. HEPATOLOGY 2004;40:1370-1378.
3. Ripoll C, Banares R, Rincon D, Catalina MV, Lo Iacono O, Salcedo M, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. HEPATOLOGY 2005;42:793-801.
4. Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. HEPATOLOGY 2002;35:478-491.
5. Gupta TK, Toruner M, Chung MK, Groszmann RJ. Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats. HEPATOLOGY 1998;28:926-931.
6. Rockey DC, Chung JJ. Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension. Gastroenterology 1998;114:344-351.
7. Gonzalez-Abraldes J, Garcia-Pagan JC, Bosch J. Nitric oxide and portal hypertension. Metab Brain Dis 2002;17:311-324.
8. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999;43:542-548.
9. MacAllister RJ, Parry H, Kimoto M, Ogawa T, Russell RJ, Hodson H, et al. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996;119:1533-1540.
10. Nijveldt RJ, Teerlink T, Siroen MP, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr 2003;22:17-22.
11. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 1999;99:3092-3095.
12. MacSween RN, Burt AD. Histologic spectrum of alcoholic liver disease. Semin Liver Dis 1986;6:221-232.
13. Mookerjee RP, Sen S, Davies NA, Hodges S, Williams R, Jalan R. TNF is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003;52:1182-1187.
14. Owen LJ, Wear JE, Keevil BG. Validation of a liquid chromatography tandem mass spectrometry assay for serum creatinine and comparison with enzymatic and Jaffe methods. Ann Clin Biochem 2006;43:118-123.
15. Tilg H, Jalan R, Kaser A, Davies NA, Offner FA, Hodges SJ, et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 2003;38:419-425.
16. Gornall AG. Determination of serum proteins by means of the biuret reaction. J Biol Chem 1949;177:751-766.
17. Atrigoni FI, Vallance P, Haworth SG, Leiper JM. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003;107:1195-1201.
18. Infante-Rivard C, Esnaola S, Villeneuve JP. Clinical and statistical validity of conventional prognostic factors in predicting short-term survival among cirrhotics. HEPATOLOGY 1987;7:660-664.
19. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. HEPATOLOGY 2001;33:464-470.
20. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
21. Maddrey WC, Boitnott JK, Bedine MS, Weber FL Jr, Mezey E, White RI Jr. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978;75:193-199.
22. Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481-1483.
23. Tsikas D, Rode I, Becker T, Nashan B, Klempnauer J, Frolich JC. Elevated plasma and urine levels of ADMA and 15(S)-8-iso-PGF2alpha in end-stage liver disease. HEPATOLOGY 2003;38:1063-1064.
24. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000;343:1467-1476.
25. McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999;19:205-219.
26. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-767.
27. Siroen MP, Teerlink T, Nijveldt RJ, Prins HA, Richir MC, van Leeuwen PA. The clinical significance of asymmetric dimethylarginine. Annu Rev Nutr 2006;26:203-228.
28. Jalan R, Pollok A, Shah SH, Madhavan K, Simpson KJ. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J Hepatol 2002;37:536-538.
29. Lluch P, Torondel B, Medina P, Segarra G, Del Olmo JA, Serra MA, et al. Plasma concentrations of nitric oxide and asymmetric dimethylarginine in human alcoholic cirrhosis. J Hepatol 2004;41:55-59.
30. McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell 2001;106:5-8.
31. Marliss EB, Chevalier S, Gougeon R, Morais JA, Lamarche M, Adegoke OA, et al. G. Elevations of plasma methylarginines in obesity and ageing are related to insulin sensitivity and rates of protein turnover. Diabetologia 2006;49:351-359.
32. Inoue R, Miyake M, Kanazawa A, Sato M, Kakimoto Y. Decrease of 3-methylhistidine and increase of NG,NG-dimethylarginine in the urine of patients with muscular dystrophy. Metabolism 1979;28:801-804.
33. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, et al. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000;87:99-105.
34. Carithers RL, Jr., Herlong HF, Diehl AM, Shaw EW, Combes B, Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med 1989;110:685-690.
35. Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KV, Malinchoc M, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. HEPATOLOGY 2005;41:353-358.
36. Mookerjee RP DN, Hodges SJ, Dalton RN, Williams R, Jalan R. Hepatic inflammation increases portal pressure through inhibition of eNOS activity - potential mechanisms [Abstract]. Gut 2006:Abstract.,zaq
37. Kielstein JT, Tsikas D, Fliser D. Effects of asymmetric dimethylarginine (ADMA) infusion in humans. Eur J Clin Pharmacol 2006;62(Suppl 13):39-44.
38. Lluch P, Mauricio MD, Vila JM, Segarra G, Medina P, Del Olmo JA, et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp Biol Med (Maywood) 2006;231:70-75.